Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart check revolution: new models may spare thousands from unneeded scans

NCT ID NCT06708000

Diagnosis Sponsor: Gødstrup Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether personalized risk models can safely reduce the number of diagnostic tests for people with new chest pain. Researchers will enroll 2,000 adults aged 30-75 and compare the model-based approach to standard care. They will also test a new laser method to measure blood flow in tiny vessels. The goal is to see if patients stay symptom-free and avoid unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clinical Likelihood (CL) Model-Based Diagnostic Strategy
What this could lead to
If successful, this could help doctors use fewer invasive tests for chest pain, saving time and discomfort for many patients.
What could go wrong
This is a large Phase 3 trial, but the approach may not be accurate for all patient groups, and the new laser test is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with de novo chest pain referred on suspicion of stable ischemic CAD * Patients capable of providing written informed consent Exclusion Criteria: * Age \<30 years or \>75 years * Known ischemic heart disease, including previous PCI (with or without stent) and bypass surgery * Unstable angina pectoris at initial consultation * Severe COPD or asthma * Severe valvular disease * Absolute or relative contraindications for Cardiac CT: * allergy to iomeron * pregnant women, including women who are potentially pregnant or lactating * reduced kidney function with an estimated glomerular filtration rate \<40 ml/min * LVEF \<45%

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina pectoris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina Pectoris arteriosclerosis disorder coronary artery disorder intermediate coronary syndrome myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina pectoris Arteriosclerosis Chronic coronary syndrome Coronary artery disease Myocardial ischemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Regional Hospital of Godstrup

    Herning, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.